S-Ol Tablet 20 mg (Olmesartan Medoxomil)

Adult dose

The recommended initial dose is 10 mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, it can be increased to 20 mg once daily. If additional blood pressure reduction is required, it can be increased up to a maximum of 40 mg once daily. The antihypertensive effect typically appears within two weeks of starting treatment, with peak effect occurring around eight weeks. In cases where blood pressure is not adequately controlled with monotherapy, thiazide diuretics such as hydrochlorothiazide may be co-administered. For optimal adherence, it is recommended to take the medication at the same time every day (e.g., in the morning). For patients with potential intravascular volume depletion (e.g., patients on diuretics, especially those with renal impairment), treatment should begin at a lower dose with careful monitoring of the patient's condition.

Child dose

Safety and efficacy for children have not yet been established.

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so treatment should be discontinued immediately if pregnancy is confirmed. It should not be used in patients with allergies to any of the components, during pregnancy or breastfeeding, in patients undergoing kidney dialysis, in patients with severe liver disease, in patients with bile duct obstruction, in patients with certain genetic lactose intolerance, in diabetic patients taking aliskiren, or in patients with moderate or severe renal impairment. Patients with reduced blood volume or body salt may experience hypotension; hence, their condition should be carefully assessed prior to use, and appropriate measures should be taken if hypotension occurs. Caution is required for patients with severe heart failure relying on kidney function and the renin-angiotensin-aldosterone system, as renal function deterioration may occur. Patients with impaired renal function or those who have undergone kidney transplants should have their serum potassium and creatinine levels regularly monitored, and it is not recommended for patients with severe renal impairment. Patients with renovascular hypertension should be cautious due to the risk of renal function deterioration. As there is a risk of hyperkalemia, patients with heart failure or renal impairment should periodically check serum potassium levels. Special precautions are necessary for patients with aortic stenosis, mitral valve stenosis, obstructive or hypertrophic cardiomyopathy when using this medication. Patients with primary aldosteronism may not respond to this medication, hence it is not recommended for them. Dizziness may occur due to blood pressure-lowering effects; therefore, operating dangerous machinery or working at heights should be avoided. When taken with other antihypertensives, there may be an enhanced blood pressure-lowering effect; when used combined with potassium-sparing diuretics or potassium supplements, serum potassium levels can dangerously rise. Co-administration with lithium should be avoided as it can increase lithium levels and lead to toxicity. Taking this medication with non-steroidal anti-inflammatory drugs can increase the risk of renal function deterioration, hence careful monitoring of renal function is necessary. Dual blockade with angiotensin-related drugs may increase the risk of hypotension, hyperkalemia, and acute renal failure; thus, blood pressure, renal function, and electrolyte status should be meticulously observed when administering concomitantly. Use during pregnancy poses serious risks to the fetus, hence should be discontinued immediately if pregnancy is confirmed, and consideration should be given to stopping breastfeeding or the medication if adverse reactions appear in the infant during lactation. Safety and efficacy for children have not yet been established. Elderly patients may have increased drug concentration in the body, so caution is warranted during administration. Symptoms of overdose may include hypotension, palpitations, and bradycardia, requiring appropriate treatment based on symptoms. This medication does not have a carcinogenic risk even with long-term use, and it has been considered low-risk in genotoxicity tests. Possible adverse reactions during administration may include dizziness, headache, abdominal pain, muscle pain, rash, etc., with severe cases presenting as angioedema or liver function abnormalities; immediate consultation with medical personnel is necessary if such symptoms occur.

Serious side effects

Hives, severe swelling (angioedema, facial edema), chest tightness, difficulty breathing, anaphylactic reactions, severe rash with fever, blisters, skin peeling, pain in the mouth/eyes mucosa, jaundice, acute renal failure, autoimmune hepatitis, severe headache, altered consciousness, visual disturbances, paralysis, markedly reduced urine output, severe edema accompanied by increased blood pressure

Mild side effects

Dizziness, headache, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, chest pain, peripheral edema, vomiting, chronic malabsorption syndrome-like gastrointestinal disease, diarrhea, hematuria, cough, epistaxis, upper respiratory infection, flu-like symptoms, pharyngitis, rhinitis, sinusitis, hair loss, pruritus, increased blood pressure, back pain, increased serum creatinine

Store this medication in a tightly sealed container to protect it from air and moisture, and it is important to maintain a temperature between 1 to 25 degrees Celsius. Such storage will help to retain the efficacy of the medication for a longer period.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle